PriceTargets.com logo

NASDAQ:EYPT - EyePoint Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $17.63
  • Forecasted Upside: 52.99 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$11.52 As of 10/25/2021 01:00 AM ET
▼ -0.49 (-4.08%)

This chart shows the closing price for EYPT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New EyePoint Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EYPT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EYPT

Analyst Price Target is $17.63
▲ +52.99% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for EyePoint Pharmaceuticals in the last 3 months. The average price target is $17.63, with a high forecast of $25.00 and a low forecast of $8.50. The average price target represents a 52.99% upside from the last price of $11.52.

This chart shows the closing price for EYPT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in EyePoint Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/4/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/2/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/29/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/28/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/26/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/13/2021HC WainwrightReiterated RatingBuy$15.00High
7/21/2021HC WainwrightReiterated RatingBuy$15.00Low
7/9/2021HC WainwrightReiterated RatingBuy$15.00Medium
7/2/2021HC WainwrightReiterated RatingBuy$15.00Low
5/26/2021HC WainwrightReiterated RatingBuy$15.00High
5/6/2021HC WainwrightLower Price TargetBuy$16.00 ➝ $15.00High
3/1/2021CowenInitiated CoverageOutperform$25.00Low
1/29/2021HC WainwrightReiterated RatingBuy$16.00Medium
1/27/2021Cantor FitzgeraldInitiated CoverageOverweight$22.00High
1/12/2021B. RileyBoost Price TargetBuy$5.00 ➝ $8.50High
10/9/2020HC WainwrightUpgradeNeutral ➝ Buy$20.00High
8/6/2020HC WainwrightReiterated RatingHoldHigh
4/6/2020B. RileyDowngradeBuy ➝ Neutral$40.00 ➝ $10.00High
4/2/2020HC WainwrightReiterated RatingHoldHigh
3/3/2020HC WainwrightReiterated RatingHoldLow
2/4/2020HC WainwrightReiterated RatingHoldHigh
1/24/2020HC WainwrightReiterated RatingHoldLow
11/11/2019HC WainwrightDowngradeBuy ➝ NeutralHigh
11/5/2019HC WainwrightReiterated RatingBuy$45.00Low
11/4/2019LaidlawInitiated CoverageBuy$50.00High
9/25/2019HC WainwrightReiterated RatingBuy$45.00Low
9/24/2019B. RileyLower Price TargetBuy$57.50 ➝ $40.00Medium
9/12/2019GuggenheimInitiated CoverageBuy$40.00High
7/12/2019HC WainwrightSet Price TargetBuy$50.00Low
5/9/2019HC WainwrightReiterated RatingBuy$45.00Low
4/2/2019HC WainwrightSet Price TargetBuy$50.00Low
1/4/2019HC WainwrightSet Price TargetBuy$50.00Medium
10/16/2018B. RileyBoost Price TargetBuy ➝ Buy$50.00 ➝ $60.00High
10/1/2018HC WainwrightReiterated RatingBuy$45.00Low
9/13/2018HC WainwrightReiterated RatingBuy$27.50Medium
9/6/2018HC WainwrightSet Price TargetBuy$30.00Low
8/2/2018HC WainwrightSet Price TargetBuy$30.00Low
7/27/2018HC WainwrightSet Price TargetBuy$30.00Low
6/26/2018HC WainwrightReiterated RatingBuy$25.00Medium
5/9/2018HC WainwrightSet Price TargetBuy$30.00High
4/13/2018HC WainwrightReiterated RatingBuy$30.00Medium
4/2/2018HC WainwrightSet Price TargetBuy$30.00N/A
3/20/2018HC WainwrightSet Price TargetBuy$50.00Medium
2/8/2018HC WainwrightSet Price TargetBuy$50.00High
1/9/2018HC WainwrightReiterated RatingBuy$50.00Low
12/15/2017HC WainwrightSet Price TargetBuy$50.00High
12/15/2017B. RileySet Price TargetBuy$50.00Medium
12/11/2017Northland SecuritiesReiterated RatingBuy$100.00Medium
12/4/2017B. RileySet Price TargetBuy$50.00Medium
11/8/2017HC WainwrightReiterated RatingBuy$50.00N/A
11/8/2017LaidlawInitiated CoverageBuy$50.00N/A
10/11/2017HC WainwrightSet Price TargetBuy$50.00N/A
9/27/2017HC WainwrightReiterated RatingBuy$50.00Low
9/12/2017HC WainwrightReiterated RatingBuy$50.00Medium
7/11/2017HC WainwrightSet Price TargetBuy$50.00High
6/24/2017HC WainwrightSet Price TargetBuy$80.00High
6/14/2017LADENBURG THALM/SH SHSet Price TargetBuy$130.00Medium
6/14/2017HC WainwrightSet Price TargetBuy$80.00Medium
6/14/2017Northland SecuritiesSet Price TargetBuy$100.00Medium
6/14/2017FBR & Co.Reiterated RatingBuyHigh
5/30/2017HC WainwrightReiterated RatingBuy$80.00High
5/30/2017Rodman & RenshawInitiated CoverageBuy$80.00High
5/15/2017FBR & Co.Reiterated RatingOutperform$70.00Medium
12/6/2016FBR & Co.Reiterated RatingOutperform$70.00N/A
(Data available from 10/26/2016 forward)

News Sentiment Rating

0.60 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/29/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/28/2021
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/28/2021
  • 4 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
8/27/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/26/2021
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/26/2021

Current Sentiment

  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

EyePoint Pharmaceuticals logo
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
Read More

Today's Range

Now: $11.52
Low: $11.44
High: $12.18

50 Day Range

MA: $10.53
Low: $9.75
High: $11.72

52 Week Range

Now: $11.52
Low: $3.51
High: $15.06

Volume

78,938 shs

Average Volume

227,030 shs

Market Capitalization

$331.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.29

Frequently Asked Questions

What sell-side analysts currently cover shares of EyePoint Pharmaceuticals?

The following Wall Street analysts have issued reports on EyePoint Pharmaceuticals in the last year: B. Riley, Cantor Fitzgerald, Cowen Inc, HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for EYPT.

What is the current price target for EyePoint Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for EyePoint Pharmaceuticals in the last year. Their average twelve-month price target is $17.63, suggesting a possible upside of 53.0%. Cowen Inc has the highest price target set, predicting EYPT will reach $25.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $8.50 for EyePoint Pharmaceuticals in the next year.
View the latest price targets for EYPT.

What is the current consensus analyst rating for EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EYPT will outperform the market and that investors should add to their positions of EyePoint Pharmaceuticals.
View the latest ratings for EYPT.

What other companies compete with EyePoint Pharmaceuticals?

Other companies that are similar to EyePoint Pharmaceuticals include Singular Genomics Systems, Rapid Micro Biosystems, Akoya Biosciences, Fluidigm, Accelerate Diagnostics, Harvard Bioscience, Codex DNA, Talis Biomedical, Astrotech, Precipio, SeqLL, Scientific Industries, BioForce Nanosciences, Pressure BioSciences and Arrayit.

How do I contact EyePoint Pharmaceuticals' investor relations team?

EyePoint Pharmaceuticals' physical mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The company's listed phone number is (617) 926-5000 and its investor relations email address is [email protected] The official website for EyePoint Pharmaceuticals is eyepointpharma.com.